Direct Impact

Concepts for which Alistair Wheeler has direct influence:

moderate-to-very-severe copd
electronic nebulizer
nebulized glycopyrrolate
arformoterol tartrate
long-term safety
trough fev1
vitro characterization

External impact

Concepts related to the work of other authors for which Alistair Wheeler has influence:

elderly copd
inhaled therapy
inhaler devices
glycopyrrolate inhalation solution
ambient air
performance comparison
nebulizer designs

Prominent publications by Alistair Wheeler

KOL-Index: 19 BackgroundLong-acting muscarinic antagonists (LAMAs) are recommended for the treatment of chronic obstructive pulmonary disease (COPD). Glycopyrrolate/eFlow® is an investigational drug–device combination of the LAMA glycopyrrolate administered by an eFlow® Closed System (eFlow® CS) nebulizer. The GOLDEN 2 (NCT01706536) and GOLDEN 6 (NCT02038829) Phase II, multicenter studies were conducted ...
Known for
25 Μg Bid | 378 | Eflow® Closed | Function Glycopyrrolate
KOL-Index: 11 BACKGROUND: Arformoterol tartrate (arformoterol, 15 μg bid) is a nebulized long-acting β2-agonist approved for maintenance treatment of COPD. METHODS: This was a multicenter, double-blind, randomized, placebo-controlled study. Patients (aged ≥ 40 years with baseline FEV1 ≤ 65% predicted, FEV1 > 0.50 L, FEV1/FVC ≤ 70%, and ≥ 15 pack-year smoking history) received arformoterol (n = 420) or ...
Known for
Event Improvements | Arformoterol Lower | Experienced Copd | Primary Time
KOL-Index: 8 BACKGROUND: The use of long-acting bronchodilators is an essential component of the management of chronic obstructive pulmonary disease (COPD). The GOLDEN 5 Phase III, randomized, active-controlled, open-label study was conducted to evaluate the long-term safety and tolerability of a nebulized glycopyrrolate formulation (SUN-101) delivered via the investigational eFlow® Closed System (eFlow® ...
Known for
Improvements Trough | Investigational Eflow® Closed | Golden 5 Phase Iii | Glycopyrrolate Eflow
KOL-Index: 6
Known for
Glycopyrrolate Inhalation Solution | Placebo-Controlled
KOL-Index: 6 BACKGROUND: SUN-101 is a combination of glycopyrrolate delivered through an innovative, electronic nebulizer, intended for the treatment of patients with COPD. The objective of this study was to assess the efficacy and safety of this new drug device combination. METHODS: Replicate Phase III randomized, double-blind, placebo-controlled studies were conducted to evaluate the efficacy and ...
Known for
Daytime Night-Time Symptoms | Nebulizer Golden | Forced Vital Capacity | 25 Μg
KOL-Index: 3 BACKGROUND: Glycopyrrolate administered by a novel, investigational eFlow® Closed System (CS) nebulizer (eFlow CS) is being evaluated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The eFlow CS is a hand-held, vibrating membrane nebulizer optimized to deliver 1 mL of glycopyrrolate solution into the lung in <3 minutes. Clinical studies have shown improvements ...
Known for
1 Ml | Glycopyrrolate Concentration Impurity | Eflow Closed Nebulizer | Apparent Increasing Trend

Sunovion Pharmaceuticals, Inc., Marlborough, Massachusetts.

© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172